Navigation Links
New evidence that chronic ulcerative stomatitis is an autoimmune disease
Date:4/13/2011

BOSTON (April 13, 2011) In the first study investigating the origins of a little-known condition called chronic ulcerative stomatitis (CUS), researchers at Tufts University School of Dental Medicine provide evidence that an autoimmune response contributes to the painful oral sores that characterize the disease. The study findings support the classification of CUS as a new autoimmune disease.

Chronic ulcerative stomatitis is characterized by painful, recurring sores in the mouth. Thus far, it has been diagnosed most frequently in white women in their 40's and 50's and may appear similar to oral erosive lichen planus. Only 39 cases of CUS have been reported in the English-language medical literature since it was identified as a clinically distinct condition in 1989, but it is likely under-diagnosed because of low awareness among clinicians and the extensiveness of the testing that would confirm its presence.

"Currently, diagnosing CUS requires a surgical biopsy which then must be sent to an outside lab for special processing for immunofluorescence microscopic examination. Accurate diagnosis is important because the usual treatment option for immunologically-mediated diseases, corticosteroids, is often not effective in treating CUS," said senior author, Lynn Solomon, DDS, MS, associate professor in the department of oral and maxillofacial pathology at Tufts University School of Dental Medicine (TUSDM).

"In previous studies, we identified that CUS patients had specific autoantibodies antibodies produced by an immune response to the body's own tissue but we weren't sure whether these autoantibodies were contributing to CUS or part of a benign biological process. In this study, we determined that autoantibodies fulfill the criteria of pathogenetic antibodies and do contribute to the disease," she continued.

In this in vitro study, the researchers applied antibodies from four CUS patients to Human Skin Equivalents (HSEs), a three-dimensional model of skin tissues. At low concentrations, the CUS antibodies appeared to have no effect. At higher concentrations, however, the researchers reported complete detachment of the surface layer of tissue, known as epithelium.

The researchers found that the CUS autoantibodies do not cause damage to the surface epithelial cells, but cause a change in the cell-binding proteins that allow the surface layer to attach to the connective tissue beneath them. This weakened cohesion results in breakdown of the tissue, which would result in the sores that characterize CUS.

"In our future research, we would like to gain a better understanding of the mechanisms linking the autoimmune response to ulcerative sores so that we can optimize approaches to managing the condition. Additional data will help us evaluate hydroxychloroquine therapy, an antimalarial drug used off-label that provides relief in many cases, but which is not well-tolerated by some patients and which may have serious side effects," said Solomon.


'/>"/>

Contact: Siobhan E. Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Related medicine news :

1. Evidence Weak to Support Many Medications for Autism: Study
2. Around 25 percent of health messages in Spanish text books are not based on scientific evidence
3. Little historical evidence to support cutting global health aid during recessions
4. More Evidence Ties Moderate Drinking to Heart Health
5. More Evidence Cancer Drug Avastin May Cause Harm
6. Health-care systems not using best evidence in decision-making
7. More Evidence That TV, Computer Time Could Harm Heart
8. Scientific evidence supports effectiveness of Chinese drug for cataracts
9. Evidence lacking for widespread use of costly antipsychotic drugs, says Stanford researcher
10. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
11. Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: